MX369952B - Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. - Google Patents
Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1.Info
- Publication number
- MX369952B MX369952B MX2016004114A MX2016004114A MX369952B MX 369952 B MX369952 B MX 369952B MX 2016004114 A MX2016004114 A MX 2016004114A MX 2016004114 A MX2016004114 A MX 2016004114A MX 369952 B MX369952 B MX 369952B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- heat shock
- dihydrodioxin
- fused
- derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical class O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 title 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 title 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula I en donde A1, A2, R4 y Q son como se define en la presente. Los compuestos de la presente invención son inhibidores del factor de choque térmico 1 (HSF1). En particular, la presente invención se refiere al uso de estos compuestos como agentes terapéuticos para el tratamiento y/o prevención de enfermedades proliferativas como el cáncer. La presente invención también se refiere a procedimientos de preparación de estos compuestos, y a composiciones farmacéuticas que los comprenden. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1317609.4A GB201317609D0 (en) | 2013-10-04 | 2013-10-04 | Inhibitor compounds |
PCT/GB2014/052992 WO2015049535A1 (en) | 2013-10-04 | 2014-10-03 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016004114A MX2016004114A (es) | 2016-06-06 |
MX369952B true MX369952B (es) | 2019-11-27 |
Family
ID=49630211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004114A MX369952B (es) | 2013-10-04 | 2014-10-03 | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. |
Country Status (21)
Country | Link |
---|---|
US (4) | US9701664B2 (es) |
EP (2) | EP3052492B1 (es) |
JP (2) | JP6500017B2 (es) |
KR (1) | KR102332232B1 (es) |
CN (1) | CN105814040B (es) |
AU (1) | AU2014330940B2 (es) |
BR (1) | BR112016007329B1 (es) |
CA (1) | CA2925182C (es) |
DK (2) | DK3521286T3 (es) |
ES (2) | ES2730705T3 (es) |
GB (1) | GB201317609D0 (es) |
HK (1) | HK1224285A1 (es) |
IL (1) | IL244452B (es) |
MX (1) | MX369952B (es) |
PL (2) | PL3521286T3 (es) |
PT (2) | PT3521286T (es) |
RU (1) | RU2671979C2 (es) |
SG (1) | SG11201602547PA (es) |
TR (1) | TR201908265T4 (es) |
WO (1) | WO2015049535A1 (es) |
ZA (1) | ZA201601223B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201505658D0 (en) * | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
US10450263B2 (en) | 2017-02-10 | 2019-10-22 | Southern Research Institute | Benzo annulenes as antiviral agents |
WO2018162312A1 (en) | 2017-03-10 | 2018-09-13 | Basf Se | Spirocyclic derivatives |
WO2019043208A1 (en) * | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
US11066357B2 (en) | 2017-12-26 | 2021-07-20 | Southern Research Institute | Benzoannulene derivatives as antiviral agents |
BR112022005899A2 (pt) * | 2019-10-17 | 2022-06-28 | Bayer Ag | Método fotoquímico para preparar (4r,4s)-4-(ciano-2-metoxifenil)-5-etoxi-2,8-dietil-1,4-dihidro-1,6-naftidirina-1,6-carboxamida |
WO2023057819A1 (en) | 2021-10-06 | 2023-04-13 | Institute Of Cancer Research | Methods of treating cancer using hsf1 pathway inhibitors |
WO2023111005A1 (en) | 2021-12-14 | 2023-06-22 | Wmt Ag | Carboxamide substituted heteroaromatic compounds for treating cancer |
WO2023194458A1 (en) | 2022-04-05 | 2023-10-12 | Wmt Ag | N-(3-(benzo[b]thiophene-2-carboxamido)-phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide derivatives and related compounds as lactate/atp production inhibitors for the treatment of cancer |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5137805A (en) | 1988-03-18 | 1992-08-11 | The General Hospital Corporation | Method of diagnosing stress condition by specific binding of human heat shock factor |
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
EP0559770A4 (en) | 1990-11-26 | 1995-04-05 | Us Commerce | Cell stress transcriptional factors |
DE19531321A1 (de) | 1995-08-25 | 1997-02-27 | Merck Patent Gmbh | Piperidinylmethyloxazolidinone |
GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
US7053052B2 (en) | 1997-01-21 | 2006-05-30 | Voellmy Richard W | Therapies involving mutated heat shock transcription factor |
AU7933298A (en) | 1997-06-27 | 1999-01-19 | Kaneka Corporation | Heat shock factor activity inhibitors |
EP1042276B1 (en) | 1997-12-23 | 2004-11-17 | Warner-Lambert Company Llc | Thiourea compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
BR9910474A (pt) | 1998-05-15 | 2001-01-02 | Astrazeneca Ab | Composto derivado de amida, processo para preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida |
IL141183A0 (en) | 1998-08-04 | 2002-02-10 | Astrazeneca Ab | Amide derivatives useful as inhibitors of the production of cytokines |
ES2211172T3 (es) | 1998-09-25 | 2004-07-01 | Astrazeneca Ab | Derivados de benzamida y su utilizacion como inhibidores de citoquinas. |
SK287238B6 (sk) | 1999-03-17 | 2010-04-07 | Astrazeneca Ab | Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
CA2366877A1 (en) | 1999-03-22 | 2000-09-28 | Stanley Michael Roberts | Chemical compounds and their uses |
US6867036B1 (en) | 1999-11-23 | 2005-03-15 | Mayo Foundation For Medical Education And Research | Gene expression by positive feedback activation of a cell type-specific promoter |
US7405080B2 (en) | 2000-03-23 | 2008-07-29 | Voellmy Richard W | Compositions and methods relating to prevention of chemotherapy-induced alopecia |
KR100804564B1 (ko) | 2000-10-30 | 2008-02-20 | 쿠도스 파마슈티칼스 리미티드 | 프탈라지논 유도체 |
DE60129606T2 (de) | 2001-09-03 | 2008-05-21 | Richard Voellmy | Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie |
US20040122008A1 (en) | 2002-09-05 | 2004-06-24 | Protter Andrew A. | Treatment of pain by inhibition of p38 MAP kinase |
WO2004004703A1 (ja) | 2002-07-04 | 2004-01-15 | Mitsui Chemicals, Inc. | メタフェニレンジアミン誘導体 |
CA2492593A1 (en) | 2002-07-15 | 2004-01-22 | Myriad Genetics, Inc. | Compounds, compositions, and methods employing same |
GB0218260D0 (en) | 2002-08-06 | 2002-09-11 | Charterhouse Therapeutics Ltd | Improvements in pharmaceutically useful compounds |
US20050113450A1 (en) | 2002-08-23 | 2005-05-26 | Atli Thorarensen | Antibacterial agents |
EP1539121A4 (en) | 2002-08-29 | 2008-08-13 | Scios Inc | METHOD OF REQUESTING OSTEOGENESIS |
AU2003272327A1 (en) | 2002-09-11 | 2004-04-30 | University Of Medicine And Dentistry Of New Jersey | Methods of bone healing |
GB0223696D0 (en) | 2002-10-14 | 2002-11-20 | Ml Lab Plc | Improved immunotherapy |
EP1575918A2 (en) | 2002-12-19 | 2005-09-21 | Neurogen Corporation | Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
EP3305919A1 (en) | 2003-06-10 | 2018-04-11 | The Trustees of Boston University | Detection methods for disorders of the lung |
KR20060054308A (ko) | 2003-07-16 | 2006-05-22 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 피부 색소침착의 치료제 |
GB0321805D0 (en) | 2003-09-18 | 2003-10-15 | Univ Wales Medicine | Human tumour growth patterns |
WO2005042496A1 (en) | 2003-10-21 | 2005-05-12 | Imclone Systems Incorporated | (benzimidazol-2-yl)-phenyl-benzyl-amine derivatives and methods for inhibiting heparanase activity |
US7427390B2 (en) | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
MX2007004480A (es) | 2004-10-15 | 2007-05-08 | Astrazeneca Ab | Quinoxalinas como inhibidores b raf. |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
WO2007041294A2 (en) | 2005-09-29 | 2007-04-12 | The Trustees Of Boston University | Methods for sensitizing cancer cells to inhibitors |
CA2629814C (en) | 2005-11-14 | 2013-12-31 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
EP1830289A1 (en) | 2005-11-30 | 2007-09-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for hepatocellular carninoma classification and prognosis |
US7919603B2 (en) | 2005-12-19 | 2011-04-05 | New York University | Heat shock RNA |
WO2008031534A1 (en) | 2006-09-11 | 2008-03-20 | Syngenta Participations Ag | Insecticidal compounds |
EP2094719A4 (en) | 2006-12-19 | 2010-01-06 | Genego Inc | NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF |
AT504702A1 (de) | 2006-12-22 | 2008-07-15 | Arc Austrian Res Centers Gmbh | Set von tumormarkern |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
US8518649B2 (en) | 2007-04-04 | 2013-08-27 | {hacek over (S)}árka O. Southern | Systems and methods for analyzing persistent homeostatic perturbations |
EP2167465A1 (en) | 2007-06-12 | 2010-03-31 | Boehringer Ingelheim International GmbH | Indolinone derivatives and their use in treating disease-states such as cancer |
MX2010006046A (es) | 2007-12-13 | 2010-06-23 | Amgen Inc | Moduladores de gamma secretasa. |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
WO2009137796A2 (en) | 2008-05-08 | 2009-11-12 | Northwestern University | Method of regulating the heat shock response |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
TW201000906A (en) | 2008-06-03 | 2010-01-01 | Cytrx Corp | Screening methods for heat-shock response modulators |
EP2307886A2 (en) | 2008-06-26 | 2011-04-13 | Dana-Farber Cancer Institute Inc. | Signatures and determinants associated with metastasis and methods of use thereof |
UA38601U (en) * | 2008-07-17 | 2009-01-12 | Львовский Национальный Медицинский Университет Имени Данилы Галицкого | 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity |
EP2660596B1 (en) | 2008-10-02 | 2018-06-13 | Gaia Medical Institute | Health test for a broad spectrum of health problems |
EP2367545A1 (en) | 2008-10-17 | 2011-09-28 | Université Libre de Bruxelles | Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy |
WO2010053655A2 (en) | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
WO2010077642A1 (en) | 2008-12-08 | 2010-07-08 | Northwestern University | Method of modulating hsf-1 |
KR101699991B1 (ko) | 2009-02-11 | 2017-01-26 | 메르크 파텐트 게엠베하 | 신규의 아미노 아자헤테로시클릭 카르복사미드 |
KR101630432B1 (ko) | 2009-08-28 | 2016-06-15 | 한국생명공학연구원 | 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물 |
AR079494A1 (es) | 2009-12-18 | 2012-02-01 | Novartis Ag | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 |
WO2012027609A2 (en) | 2010-08-25 | 2012-03-01 | The Board Of Trustees Of The University Of Illinois | Extracts from pirin+ and pirin- plants and uses thereof |
WO2012154858A1 (en) | 2011-05-09 | 2012-11-15 | Whitehead Institute For Biomedical Research | Chaperone interaction assays and uses thereof |
US20140302042A1 (en) | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
KR20140057374A (ko) | 2011-09-02 | 2014-05-12 | 노파르티스 아게 | Hsf1-관련 질환을 치료하기 위한 유기 조성물 |
US9696313B2 (en) | 2011-10-06 | 2017-07-04 | Whitehead Institute For Biomedical Research | HSF1 as a marker in tumor prognosis and treatment |
EP2877859A4 (en) | 2012-05-03 | 2016-08-03 | Whitehead Biomedical Inst | HSF1 AND HSF1 CSS GENES AND USES THEREOF |
KR101507221B1 (ko) | 2012-05-14 | 2015-03-31 | 이화여자대학교 산학협력단 | 두충으로부터 분리된 화합물을 포함하는 열충격단백질 유도 활성을 갖는 조성물 |
EP2806274A1 (en) | 2013-05-24 | 2014-11-26 | AIT Austrian Institute of Technology GmbH | Lung cancer diagnostic method and means |
GB201317609D0 (en) * | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
-
2013
- 2013-10-04 GB GBGB1317609.4A patent/GB201317609D0/en not_active Ceased
-
2014
- 2014-10-03 PT PT191647247T patent/PT3521286T/pt unknown
- 2014-10-03 CN CN201480066360.XA patent/CN105814040B/zh active Active
- 2014-10-03 JP JP2016519879A patent/JP6500017B2/ja active Active
- 2014-10-03 ES ES14781644T patent/ES2730705T3/es active Active
- 2014-10-03 WO PCT/GB2014/052992 patent/WO2015049535A1/en active Application Filing
- 2014-10-03 CA CA2925182A patent/CA2925182C/en active Active
- 2014-10-03 RU RU2016117056A patent/RU2671979C2/ru active
- 2014-10-03 DK DK19164724.7T patent/DK3521286T3/da active
- 2014-10-03 EP EP14781644.1A patent/EP3052492B1/en active Active
- 2014-10-03 ES ES19164724T patent/ES2902124T3/es active Active
- 2014-10-03 PL PL19164724T patent/PL3521286T3/pl unknown
- 2014-10-03 PT PT14781644T patent/PT3052492T/pt unknown
- 2014-10-03 AU AU2014330940A patent/AU2014330940B2/en active Active
- 2014-10-03 SG SG11201602547PA patent/SG11201602547PA/en unknown
- 2014-10-03 PL PL14781644T patent/PL3052492T3/pl unknown
- 2014-10-03 EP EP19164724.7A patent/EP3521286B1/en active Active
- 2014-10-03 TR TR2019/08265T patent/TR201908265T4/tr unknown
- 2014-10-03 MX MX2016004114A patent/MX369952B/es active IP Right Grant
- 2014-10-03 US US15/026,911 patent/US9701664B2/en active Active
- 2014-10-03 BR BR112016007329-0A patent/BR112016007329B1/pt active IP Right Grant
- 2014-10-03 DK DK14781644.1T patent/DK3052492T3/da active
- 2014-10-03 KR KR1020167011710A patent/KR102332232B1/ko active IP Right Grant
-
2016
- 2016-02-23 ZA ZA2016/01223A patent/ZA201601223B/en unknown
- 2016-03-06 IL IL244452A patent/IL244452B/en active IP Right Grant
- 2016-10-24 US US15/332,472 patent/US10189821B2/en active Active
- 2016-10-28 HK HK16112461.7A patent/HK1224285A1/zh unknown
-
2018
- 2018-12-06 US US16/212,455 patent/US11124501B2/en active Active
-
2019
- 2019-03-18 JP JP2019049733A patent/JP6732071B2/ja active Active
-
2021
- 2021-08-19 US US17/406,640 patent/US11787786B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX369952B (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. | |
PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
GB201209613D0 (en) | New compounds | |
MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
IN2014MN00988A (es) | ||
GB201209609D0 (en) | New compounds | |
MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
WO2014138616A3 (en) | Pyrazole compounds and methods of use thereof | |
EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний | |
MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. | |
UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |